Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 29, 2015 6:07 AM ET

Pharmaceuticals

Company Overview of Bayer HealthCare AG

Company Overview

Bayer HealthCare AG discovers, develops, manufactures, and markets products that help to prevent, diagnose, and treat diseases for humans and animals worldwide. The company operates through four divisions: Animal Health, Consumer Care, Medical Care, and Pharmaceuticals. The Animal Health division produces and distributes various animal health and care products, which include flea and tick-control solutions, anti-infective products, and endoparasitics for farm and companion animals. The Consumer Care division offers over-the-counter products, such as analgesics, gastrointestinal products, dermatological/topical products, cough and cold remedies, and multivitamins and dietary supplements. It s...

Building Q 30

Leverkusen,  51368

Germany

Founded in 1863

Phone:

49 214 301

Fax:

49 214 30 50731

Key Executives for Bayer HealthCare AG

Chairman of Management Board
Age: 53
Chief Financial Officer and Head of Central Administration & Organization
Age: 58
Head of Product Supply and Member of Management Board
Age: 59
Chief Operating Officer of Bayer CropScience and Member of Executive Committee
Age: 61
Head of Global Drug Discovery
Age: 52
Compensation as of Fiscal Year 2015.

Bayer HealthCare AG Key Developments

Bayer HealthCare and Union Settle Four Year Contract

Bayer HealthCare and the union representing some 450 workers in Berkeley agreed on a four-year contract that includes annual pay increases of at least 3.2%. The new contract, settled a month before the current four-year pact expires on Aug. 25, was ratified by members of the International Longshore and Warehouse Union Local 6. The new deal ends Aug. 24, 2019. Production and supply workers at the Berkeley facility - the only unionized biotech manufacturing workforce in the United States - currently make about $67,000 a year, according to a report last year from Bayer to Berkeley city offiicials. Bayer this spring broke ground on a $100 million testing facility in Berkeley, where it currently makes and tests Bayer's second-best-selling product, the blood-clotting drug Kogenate FS for hemophilia A patients. But Bayer, for the first time, plans to make two products in Berkeley, if the Food and Drug Administration later this year approves a hemophilia A treatment called Kovaltry.

Bayer HealthCare and Sprint Bioscience AB Collaborate to Develop Oncological Drug Candidates

Bayer HealthCare and Sprint Bioscience AB have entered into a collaboration and license agreement for the research, development, and commercialization of new oncological drug candidates. Under the agreement, Sprint Bioscience licenses an early-stage inhibitor program targeting tumor metabolism to Bayer. Subsequently, Bayer will have full control over further development and worldwide commercialization rights for potential cancer therapeutics and diagnostics.

Bayer Healthcare Wins US FDA Approval for Finacea for Treating Inflammatory Papules and Pustules of Mild to Moderate Rosacea

Bayer HealthCare reported that it has received the US Food & Drug Administration's (FDA) approval for Finacea (azelaic acid) Foam, 15% for topical treatment of the inflammatory papules and pustules of mild to moderate rosacea. According to the company, Papulopustular rosacea is a skin disease causing inflammatory lesions (papules and pustules) on the nose, cheeks, chin and forehead. The company added that Finacea Foam was developed as part of a research and development collaboration with Foamix Pharmaceuticals utilising Foamix's proprietary foam technology platform. Under the license agreement between the two companies, Foamix is entitled to royalties and certain milestone payments upon commercialisation of Finacea Foam. Beginning September 2015, Finacea Foam will be marketed in the US by Bayer HealthCare and will be available by prescription.

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
December 17, 2014
Bayer HealthCare AG, Legend®/Hyonate® And Marquis®
Fund Raising
December 10, 2014
Versant Venture Capital V, L.P.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Bayer HealthCare AG, please visit healthcare.bayer.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.